HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Cutaneous fibrosarcoma — Clinical Guidelines

Overview

Cutaneous fibrosarcoma is a rare, locally aggressive soft tissue sarcoma that primarily affects the skin and subcutaneous tissues, often presenting as a firm, painless nodule. It typically arises in the dermis and can mimic benign skin lesions, necessitating histopathological confirmation for accurate diagnosis 24.

Diagnosis

Clinical Presentation: Firm, slowly growing nodule, often on the trunk or extremities 24.

Histopathological Examination: Essential for diagnosis, showing fibroblastic proliferation with storiform pattern 24.

Immunohistochemistry: Often positive for vimentin and CD10, negative for cytokeratins 24.

Imaging: MRI or CT may be used to assess extent and local invasion 24.

Grading: Based on mitotic activity and tumor necrosis; low-grade typically has better prognosis 24.

Management

Surgical Excision: Wide local excision with clear margins is the primary treatment 24.

Adjuvant Therapy: Not routinely indicated for low-grade fibrosarcomas; considered for high-grade cases with high risk of recurrence 24.

Radiation Therapy: May be used postoperatively in high-risk cases or for unresectable tumors 24.

Reconstruction: Often required post-excision, depending on the extent of resection 24.

Special Populations

Pediatrics: Limited data; management similar to adults but with closer monitoring due to growth considerations 9.

Elderly: Surgery may need to be tailored considering comorbidities and functional status 24.

Key Recommendations

Surgical Excision with Clear Margins is essential for definitive treatment of cutaneous fibrosarcoma (Evidence: Strong 24).

Histopathological Confirmation is critical for accurate diagnosis and differentiation from benign lesions (Evidence: Strong 24).

Consider Adjuvant Therapy for high-grade fibrosarcomas with high recurrence risk, though evidence is primarily based on expert consensus (Evidence: Expert opinion 24).

Postoperative Imaging may be warranted to assess for residual disease or recurrence, especially in high-risk cases (Evidence: Moderate 24).

Reconstructive Surgery should be individualized based on the extent of resection and patient factors (Evidence: Moderate 24).

References

1 Yao J, Lin Y, Chen L. Levetiracetam and severe cutaneous adverse reactions: insights from FAERS database analysis. Expert opinion on drug safety 2026. link 2 Xiao Y, Guo H, Deng L, Huang J, Sun Q. Severe cutaneous adverse reactions linked to medications in children and adolescents: a pharmacovigilance study based on the FDA Adverse Event Reporting System database. International journal of clinical pharmacy 2026. link 3 Zhu J, Huo X, Li X, Yang Z, Huang Z, Wu J et al.. Severe cutaneous adverse reactions associated with novel antiandrogens: A disproportionality analysis of three databases. International journal of cancer 2025. link 4 Martín-Lluesma S, Svane IM, Dafni U, Vervita K, Karlis D, Dimopoulou G et al.. Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis. Annals of oncology : official journal of the European Society for Medical Oncology 2024. link 5 Pholmoo N, Thaiwat S, Klaewsongkram J. Severe vitamin D deficiency increases the risk of severe cutaneous adverse reactions. Experimental dermatology 2024. link 6 Yarza R, Bover M, Herrera-Juarez M, Rey-Cardenas M, Paz-Ares L, Lopez-Martin JA et al.. Efficacy of T-Cell Receptor-Based Adoptive Cell Therapy in Cutaneous Melanoma: A Meta-Analysis. The oncologist 2023. link 7 Shellenberger RA, Gowda S, Kurn H, Albright J, Mayo MH. Vitamin D insufficiency and serum levels related to the incidence and stage of cutaneous melanoma: a systematic review and meta-analysis. Melanoma research 2023. link 8 Liyanage UE, MacGregor S, Bishop DT, Shi J, An J, Ong JS et al.. Multi-Trait Genetic Analysis Identifies Autoimmune Loci Associated with Cutaneous Melanoma. The Journal of investigative dermatology 2022. link 9 Dégboé B, Koudoukpo C, Almeida CD, Kouassi A, Nguessie C, Akpadjan F et al.. Severe Cutaneous Adverse Drug Reactions in Children: Epidemiological, Clinical and Etiological Aspects in Dermatology-Venereology Unit at National and Teaching Hospital of Cotonou. West African journal of medicine 2022. link 10 James J, Mohamed AB, Hussain FS, Rani J, Varadarajan S. Clinical Pattern and Causality Assessment of Drug-induced Cutaneous Reactions in a Tertiary Care Hospital in India: A Prospective Study. Current drug safety 2022. link 11 Lopes FCPS, Sleiman MG, Sebastian K, Bogucka R, Jacobs EA, Adamson AS. UV Exposure and the Risk of Cutaneous Melanoma in Skin of Color: A Systematic Review. JAMA dermatology 2021. link 12 Sato T, Cheng CL, Park HW, Kao Yang YH, Yang MS, Fujita M et al.. Real-world evidence of population differences in allopurinol-related severe cutaneous adverse reactions in East Asians: A population-based cohort study. Clinical and translational science 2021. link 13 Ambe K, Ohya K, Takada W, Suzuki M, Tohkin M. In Silico Approach to Predict Severe Cutaneous Adverse Reactions Using the Japanese Adverse Drug Event Report Database. Clinical and translational science 2021. link 14 Hashizume H, Abe R, Azukizawa H, Fujiyama T, Hama N, Mizukawa Y et al.. Confusion in determination of two types of cutaneous adverse reactions to drugs, maculopapular eruption and erythema multiforme, among the experts: A proposal of standardized terminology. The Journal of dermatology 2020. link 15 Kikuchi S, Nobeyama Y, Saeki H, Asahina A. Characteristics of cutaneous adverse drug reactions caused by triple-combination drug therapy used for Helicobacter pylori eradication. The Journal of dermatology 2020. link 16 Panickar R, Wo WK, Ali NM, Tang MM, Ramanathan GRL, Kamarulzaman A et al.. Allopurinol-induced severe cutaneous adverse drug reactions: Risk minimization measures in Malaysia. Pharmacoepidemiology and drug safety 2020. link 17 Dubin DP, Dinehart SM, Farberg AS. Level of Evidence Review for a Gene Expression Profile Test for Cutaneous Melanoma. American journal of clinical dermatology 2019. link 18 Kang MG, Sohn KH, Kang DY, Park HK, Yang MS, Lee JY et al.. Analysis of Individual Case Safety Reports of Severe Cutaneous Adverse Reactions in Korea. Yonsei medical journal 2019. link 19 Mirsky R, Prado G, Svoboda R, Glazer A, Rigel D. Management Decisions Made by Physician Assistants and Nurse Practitioners in Cutaneous Malignant Melanoma Patients: Impact of a 31-Gene Expression Profile Test. Journal of drugs in dermatology : JDD 2018. link 20 Chopra D, Sharma V, Kapoor R, Dwivedi S. An observational study of cutaneous adverse drug reactions in a teaching hospital. International journal of clinical pharmacy 2015. link 21 Charlton ME, Sapkota K, Eide MJ, Olson DB, McKeen K, Platz CE et al.. What increased registry outreach may mean for cutaneous melanoma surveillance: impact of changes in Iowa. Journal of registry management 2014. link 22 Kim SC, Newcomb C, Margolis D, Roy J, Hennessy S. Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study. Arthritis care & research 2013. link 23 Ferrándiz L, Ruiz-de-Casas A, Martin-Gutierrez FJ, Peral-Rubio F, Mendez-Abad C, Rios-Martin JJ et al.. Effect of teledermatology on the prognosis of patients with cutaneous melanoma. Archives of dermatology 2012. link 24 Webber SA, Siller G, Soyer HP. Pigmented spindle cell naevus of Reed: a controversial diagnostic entity in Australia. The Australasian journal of dermatology 2011. link 25 Wolf R, Davidovici B. Severe cutaneous adverse drug reactions: who should treat, where and how?: Facts and controversies. Clinics in dermatology 2010. link 26 Durbec F, Vitry F, Granel-Brocard F, Lipsker D, Aubin F, Hédelin G et al.. The role of circumstances of diagnosis and access to dermatological care in early diagnosis of cutaneous melanoma: a population-based study in France. Archives of dermatology 2010. link 27 Grange F, Vitry F, Granel-Brocard F, Lipsker D, Aubin F, Hédelin G et al.. Variations in management of stage I to stage III cutaneous melanoma: a population-based study of clinical practices in France. Archives of dermatology 2008. link 28 Stanganelli I, Seidenari S, Serafini M, Pellacani G, Bucchi L. Diagnosis of pigmented skin lesions by epiluminescence microscopy: determinants of accuracy improvement in a nationwide training programme for practical dermatologists. Public health 1999. link 29 Perez M. Advances in dermatologic surgery. Dermatologic clinics 1997. link70410-1) 30 Merlino LA, Sullivan KJ, Whitaker DC, Lynch CF. The independent pathology laboratory as a reporting source for cutaneous melanoma incidence in Iowa, 1977-1994. Journal of the American Academy of Dermatology 1997. link70175-0) 31 Cristofolini M, Zumiani G, Bauer P, Cristofolini P, Boi S, Micciolo R. Dermatoscopy: usefulness in the differential diagnosis of cutaneous pigmentary lesions. Melanoma research 1994. link 32 Stürchler D, Mittelholzer ML, Kerr L. How frequent are notified severe cutaneous adverse reactions to Fansidar?. Drug safety 1993. link 33 Szekeres E, Bertenyi C, Korom I. Clinical characteristics of cutaneous melanoma in southeastern Hungary. The Journal of dermatologic surgery and oncology 1989. link 34 Brooks NA. Curettage and shave excision. A tissue-saving technic for primary cutaneous carcinoma worthy of inclusion in graduate training programs. Journal of the American Academy of Dermatology 1984. link

Cutaneous fibrosarcoma